Kalvista Pharmaceuticals Net Worth
Kalvista Pharmaceuticals Net Worth Breakdown | KALV |
Kalvista Pharmaceuticals Net Worth Analysis
Kalvista Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Kalvista Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Kalvista Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Kalvista Pharmaceuticals' net worth analysis. One common approach is to calculate Kalvista Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Kalvista Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Kalvista Pharmaceuticals' net worth. This approach calculates the present value of Kalvista Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Kalvista Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Kalvista Pharmaceuticals' net worth. This involves comparing Kalvista Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Kalvista Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Kalvista Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Kalvista Pharmaceuticals' net worth research are outlined below:
| Kalvista Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (126.64 M) with loss before overhead, payroll, taxes, and interest of (91 M). | |
| Kalvista Pharmaceuticals currently holds about 142.08 M in cash with (89.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78. | |
| Kalvista Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: KalVista Pharmaceuticals, Inc. Insider Paul K. Audhya Sells 2,394 Shares of Stock |
Kalvista Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Kalvista Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kalvista Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 5th of July 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 5th of July 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Know Kalvista Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kalvista Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kalvista Pharmaceuticals backward and forwards among themselves. Kalvista Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kalvista Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Woodline Partners Lp | 2024-12-31 | 1.3 M | |
| Stempoint Capital Lp | 2024-12-31 | 992.8 K | |
| Emerald Advisers, Llc | 2024-12-31 | 836 K | |
| Geode Capital Management, Llc | 2024-12-31 | 822.4 K | |
| Dafna Capital Management Llc | 2024-12-31 | 811.7 K | |
| Schroder Investment Management Group | 2024-12-31 | 805.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 696 K | |
| Silverarc Capital Management, Llc | 2024-12-31 | 612.2 K | |
| Saturn V Capital Management Llc | 2024-12-31 | 556.5 K | |
| Vr Adviser, Llc | 2024-12-31 | 6.2 M | |
| Suvretta Capital Management, Llc | 2024-12-31 | 4.9 M |
Follow Kalvista Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 563.12 M.Market Cap |
|
Project Kalvista Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.09) | (1.03) | |
| Return On Capital Employed | 18.02 | 18.92 | |
| Return On Assets | (1.09) | (1.03) | |
| Return On Equity | 0.16 | 0.17 |
When accessing Kalvista Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Kalvista Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Kalvista Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Kalvista Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kalvista Pharmaceuticals. Check Kalvista Pharmaceuticals' Beneish M Score to see the likelihood of Kalvista Pharmaceuticals' management manipulating its earnings.
Evaluate Kalvista Pharmaceuticals' management efficiency
Kalvista Pharmaceuticals has return on total asset (ROA) of (0.7162) % which means that it has lost $0.7162 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.259) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.17 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03). At this time, Kalvista Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 11.7 M in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (37.75) | (35.86) | |
| Tangible Book Value Per Share | (37.75) | (35.86) | |
| Enterprise Value Over EBITDA | (11.65) | (12.23) | |
| Price Book Value Ratio | (2.06) | (1.96) | |
| Enterprise Value Multiple | (11.65) | (12.23) | |
| Price Fair Value | (2.06) | (1.96) | |
| Enterprise Value | 84.4 M | 131.3 M |
The decision-making processes within Kalvista Pharmaceuticals are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 76.3323 | Revenue | Quarterly Revenue Growth 0.307 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kalvista Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kalvista Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kalvista Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kalvista Pharmaceuticals Corporate Filings
F4 | 25th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 3rd of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 16th of January 2025 Other Reports | ViewVerify | |
8K | 16th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Kalvista Pharmaceuticals Earnings per Share Projection vs Actual
Kalvista Pharmaceuticals Corporate Management
| Jarrod Aldom | Vice Communications | Profile | |
| Nicole Sweeny | Chief Officer | Profile | |
| Ryan Baker | Head Relations | Profile | |
| Brian Piekos | Chief Officer | Profile | |
| John McKune | VP Fin | Profile | |
| Thomas MBA | CEO Director | Profile |
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.